Biomarkers of Response to Checkpoint Inhibitors beyond PD-L1 in Lung Cancer

By
Justin.choi
-
0
221
In this review, scientists address the state of PD-L1 testing in lung cancer, the role for tumor mutation burden as a predictive biomarker
[Modern Pathology]

Sorry, but the selected Zotpress account can't be found.

Abstract